Canaccord Genuity Group Downgrades Arcellx (NASDAQ:ACLX) to Hold

Arcellx (NASDAQ:ACLX) was downgraded by Canaccord Genuity Group from a “strong-buy” rating to a “hold” rating in a note issued to investors on Monday,Zacks.com reports.

Several other equities analysts also recently issued reports on ACLX. Wolfe Research initiated coverage on shares of Arcellx in a research note on Tuesday, November 18th. They issued a “peer perform” rating for the company. Evercore set a $115.00 target price on Arcellx in a report on Monday. UBS Group downgraded Arcellx from a “buy” rating to a “neutral” rating and raised their price target for the stock from $100.00 to $115.00 in a research note on Tuesday. HC Wainwright cut Arcellx from a “buy” rating to a “neutral” rating and set a $115.00 price objective for the company. in a research note on Monday. Finally, Guggenheim reissued a “buy” rating on shares of Arcellx in a report on Monday, November 24th. Two research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $111.64.

Arcellx Trading Down 0.0%

Shares of Arcellx stock opened at $113.71 on Monday. The company has a fifty day simple moving average of $68.84 and a 200-day simple moving average of $75.38. The stock has a market cap of $6.57 billion, a price-to-earnings ratio of -28.93 and a beta of 0.36. Arcellx has a 12-month low of $47.86 and a 12-month high of $114.26.

Insiders Place Their Bets

In other Arcellx news, insider Christopher Heery sold 5,882 shares of Arcellx stock in a transaction that occurred on Wednesday, January 14th. The stock was sold at an average price of $68.51, for a total value of $402,975.82. Following the transaction, the insider directly owned 23,749 shares in the company, valued at approximately $1,627,043.99. This trade represents a 19.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last ninety days, insiders sold 19,450 shares of company stock worth $1,283,477. 8.35% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Arcellx

Hedge funds have recently modified their holdings of the stock. MAI Capital Management purchased a new position in Arcellx in the 3rd quarter valued at $26,000. CWM LLC raised its position in Arcellx by 267.0% during the 3rd quarter. CWM LLC now owns 345 shares of the company’s stock worth $28,000 after buying an additional 251 shares during the last quarter. State of Wyoming acquired a new stake in shares of Arcellx in the 2nd quarter worth $28,000. Ramirez Asset Management Inc. purchased a new stake in shares of Arcellx in the third quarter valued at about $41,000. Finally, Abich Financial Wealth Management LLC purchased a new stake in shares of Arcellx in the third quarter valued at about $62,000. 96.03% of the stock is owned by institutional investors and hedge funds.

Arcellx News Summary

Here are the key news stories impacting Arcellx this week:

• Positive Sentiment: Gilead Sciences agreed to acquire Arcellx for $115.00 per share in cash plus one contingent value right worth $5.00 if milestones are met, implying up to ~$7.8 billion — a takeover premium that drove a large rally. Gilead acquisition release
• Positive Sentiment: Market reaction: the deal triggered a premarket surge (roughly 75–80% intraday move at announcement) and sharply elevated trading volumes as the market re‑priced ACLX to reflect the cash consideration. Reuters coverage
• Neutral Sentiment: HC Wainwright updated FY2030 EPS expectations materially (analyst projects $4.95/sh) but kept a “Neutral” rating and $115 price objective — effectively aligned with the deal price and not implying incremental upside beyond the offer. MarketBeat report
• Negative Sentiment: Multiple brokerages downgraded ACLX to “hold”/”equal weight” (Truist, Baird, Canaccord, Needham, Wells Fargo, Citigroup), signaling limited upside above the deal price and reducing buy‑side conviction. Example coverage: Truist/Benzinga. Benzinga downgrades roundup
• Negative Sentiment: Several law firms (Kahn Swick & Foti, Halper Sadeh, Ademi, Monteverde) announced investigations into whether the $115 + $5 CVR consideration is fair — potential litigation could seek a higher price, delay closing or increase transaction risk/uncertainty. KSF investor alert

About Arcellx

Arcellx, Inc (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company’s proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.

The company’s pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.